Lirentelimab-AK002-DataSheet-生命科學(xué)試劑-MCE

Hotline:400-820-3792Inhibitors?ScreeningLibraries?Proteinswww.MedChemELirentelimabCat.No.:HY-P99371CASNo.:2283348-97-8Synonyms:AK002;Anti-Siglec-8ReferenceAntibody(lirentelimab)作?靶點(diǎn):Apoptosis作?通路:Apoptosis儲(chǔ)存?式:PleasestoretheproductundertherecommendedconditionsintheCertificateofAnalysis.BIOLOGICALACTIVITY?物活性Lirentelimab(AK002)?種?化IgG1單克隆抗體，靶向唾液酸結(jié)合的Ig樣凝集素8(SIGLEC8)。Lirentelimab誘導(dǎo)IL-5激活的嗜酸性粒細(xì)胞細(xì)胞凋亡并抑制IL-5介導(dǎo)的肥?細(xì)胞激活。Lirentelimab可?于嗜酸性胃炎、??指腸炎的研究。體外研究MonovalentLirentelimabfragmentantigen-binding(fab)bindstorecombinantSIGLEC8extracellulardomain(ECD)isdeterminedtobe464pM[1].LirentelimabshowshighaffinitytoSIGLEC8invitro,toSIGLEC8expressedoneosinophils,andtoNKcellsviaitsFcregioninhumanblood[1].Lirentelimab(1μg/mL)selectivelybindstoeosinophilsinhumanperipheralblood,andeosinophilsandmastcellsfromhumanlungtissue[1].Lirentelimab(0.0001-100μg/mL;30min)inducesapoptosisofIL-5-activatedeosinophils[1].Lirentelimab(30min)showspotentantibody-dependentcell-mediatedcytotoxicity(ADCC)ActivityonhumaneosinophilswithanEC50valueof1.9ng/mLtoeosinophilsinperipheralbloodleukocytes(PBL)preparationsfromhealthydonors[1].Lirentelimabreduceseosinophilnumbersinexvivohumantissue[1].ApoptosisAnalysis[1]CellLine:EosinophilsConcentration:10μg/mL-1pg/mLIncubationTime:30minResult:Dose-dependentlyinducedapoptosisofIL-5-activated(50ng/mL)eosinophils.體內(nèi)研究Lirentelimab(100μg;i.v.once)significantlyinhibitsIgE-mediatedmastcellactivationinamicemodelofsystemicanaphylaxis[1].1/2MasterofBioactiveMolecules—您?邊的抑制劑?師www.MedChemEAnimalModel:Humanizedmice(NSG-SGM3)engraftswithhumanthymus,liver,andHSC[1]Dosage:100μgAdministration:Intravenousinjection;100μg,onceResult:Completelypreventedpassivesystemicanaphylaxis(PSA)asshownbyalackofchangeinrectaltemperatureandsymptomscoresinmice.REFERENCES[1].YoungbloodBA,etal.AK002,aHumanizedSialicAcid-BindingImmunoglobulin-LikeLectin-8AntibodythatInducesAntibody-DependentCell-MediatedCytotoxicityagainstHumanEosinophilsandInhibitsMastCell-MediatedAnaphylaxisinMice.IntArchAllergyImmunol.2019;180(2):91-102.McePdfHeightCaution:Producthasnotbeenfullyvalidatedformedicalapplications.Forresearchu